Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Bayer Aktiengesellschaft (BAYRY) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer Aktiengesellschaft (BAYRY) - $25 value - yours FREE >>
Image: Bigstock
Bayer (BAYRY) Raises Offer to Buy Monsanto to $125/Share
It seems that German-based Bayer AG (BAYRY - Free Report) won’t let go U.S.-based Monsanto Company that easily in its attempt to create a global leader in agriculture. Bayer announced that it has upped its all-cash offer to Monsanto shareholders from $122 per share to $125 per share. Bayer said that though the offer was verbally made to Monsanto on Jul 1, it was formally submitted to the latter on Jul 9.
Bayer’s revised offer represents a premium of 40% over Monsanto’s closing share price on May 9, 2016. Bayer said that its increased offer has addressed Monsanto’s questions regarding financing and regulatory matters. It further stated that it was willing to make certain commitments to regulators to complete the deal.
BAYER A G -ADR Price
BAYER A G -ADR Price | BAYER A G -ADR Quote
Bayer has also added a reverse antitrust break fee of $1.5 billion. The company confirmed that its offer provides transaction certainty and is not subject to a financing condition. The company believes in its ability to gain all essential regulatory approvals in a timely manner given complementary geographic and product portfolios.
Monsanto said that it would comment only after its board of directors complete the review of Bayer’s latest proposal. Monsanto's shares were up 3.1% on the news.
MONSANTO CO-NEW Price
MONSANTO CO-NEW Price | MONSANTO CO-NEW Quote
We note that Monsanto had rejected the initial offer of $122 per share in May 2016 citing that the offer significantly undervalued the company. However, the company was open to more talks.
As per a Bloomberg report, Monsanto is exploring an alternative transaction. The company is looking into the possibility of acquiring the German chemical company BASF SE’s (BASFY - Free Report) agriculture-solutions unit.
We expect investor focus to remain on updates from the Bayer-Monsanto transaction, going ahead.
While Bayer is a Zacks Rank #3 (Hold) stock, Monsanto carries a Zacks Rank #5 (Strong Sell). Innoviva, Inc. (INVA - Free Report) is a better-ranked stock in the health care sector sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>